Formulation Development for Biologics & Bioconjugates

Products & Services

Information

Customized for your molecule and development phase, Abzena align your drug to your preferred target product profile (TPP) with a comprehensive range of formulation development packages including stable liquid and lyophilized formulations. We select your best lead candidate through screening of optimal buffer conditions and formulation options to inform successful drug substance manufacturing conditions and drug product forms that support long-term stability.
Abzena
415
Abzena is the leading end-to-end bioconjugate (ADCs, AOCs, RDCs) and complex biologics CDMO + CRO. From discovery through commercial, we support customers with fully integrated programs or individual services that de-risk and streamline the development of new medicines for patients in need. With over two decades of experience, 2000+ conjugates developed and over 200+ cell lines developed, we have the expertise and technical know-how to rapidly progress your biopharmaceutical to IND and beyond. And with footholds in the US and UK, we offer a simplified and secure supply chain. Fully integrated CDMO+CRO support across multiple modalities: -Monoclonal Antibodies (mAbs) -Antibody-Drug Conjugates (ADCs) -Antibody-Oligonucleotide Conjugates (AOCs) -Radionuclide Antibody-Conjugates (RACs) & Radionuclide Drug-Conjugates (RDCs) -Bispecific Antibodies (bsAbs) -Fusion Proteins -Cytokines -Recombinant & Conjugate Vaccines -Nanoparticles With Capabilities Ranging From: • Early-Stage Research & Discovery, Design and Lead Selection • Robust Analytics, Bioassays, and Immunogenicity • Bioconjugation & Chemistry • Antibody Engineering and Developability • Mammalian Cell Line Development • Linker Payload Design and Synthesis • Analytical Method & Formulation Development • Process Development and cGMP Manufacturing up to 2000L • Technology Transfer & Scale-Up • Regulatory Support - Over 24 years of experience developing 2000+ conjugations, 1400+ linker-payloads synthesized and 200+ cell lines -Champion Award Winner in Global Biologics at the 2025 CDMO Leadership Awards - Unique end-to-end value proposition ranging from antibody discovery to clinical-scale GMP biologic drug substance manufacture - Scientific expertise to deliver at high quality, low cost and compressed timelines - Global customer base, including most of the top 20 biopharmaceutical companies -Supply chain security with fully integrated US & UK facilities that can handle highly potent and cytotoxic molecules. - 14 products utilizing Abzena’s technologies in clinical trials - Biologics discovery, design, optimization, characterization, lead selection, cell line development, process development & GMP manufacture for supply from preclinical through commercial scale. - Bioconjugate (including ADCs, AOCs, RDCs) discovery, design, optimization, characterization, lead selection, cell line development, process development & GMP manufacture for supply from preclinical through commercial scale. - Synthesis, analysis, and GMP manufacture of APIs, payloads, and highly potent compounds (HPAPI) and cytotoxic - Discovery to Phase II accelerated development for antibody-drug conjugates including antibodies, linkers and payloads. -Tech transfer and commercial scale manufacturing up to 2000L for biologics and bioconjugates

Log in

See all the content and easy-to-use features by logging in or registering!